STMN1 and breast carcinoma: Unlike previous studies looking at stathmin as a potential predictive marker, predominantly in in vitro breast cancer studies, in this study we were able to test and confirm the association in clinical samples from patients treated with the drug of interest; using data from a well-annotated prospectively collected patient series.